Mesoblast Stock Plummets 31% After Trial Looks Unlikely To Meet Endpoint

Biotechnology company Mesoblast (NASDAQ: MESO) shares are plummeting premarket after the company said that its COVID-19 treatment was unlikely to meet its primary endpoint.

Mesoblast shares are down 31.83% on Friday at $9.25 following Thursday’s close at $13.57. Its Australian-listed stock price fell 36.07% to A$2.41 after the news.

In a press release, the company said that the trial was aiming to achieve a primary endpoint of a 43% reduction in mortality at 30 days for treatment with remestemcel-L on top of maximal care in a trial of 300 patients with the mortality reduction target based on pilot data observed during the initial stages of the pandemic.

WELCOME BONUS - Free Share Bundle When You Invest £50! Get up to £500 cashback for investing with IG.

Invest in 15,000+ shares and ETFs. Open an account now, invest at least £50, and you’ll get a free share bundle worth between £40 and £200. T&Cs apply.

5.0

Open Account Spread bets and CFDs are complex instruments and come with a high risk of losing money rapidly due to leverage. 68% of retail investor accounts lose money when trading spread bets and CFDs with this provider. You should consider whether you understand how spread bets and CFDs work, and whether you can afford to take the high risk of losing your money.

However, the Data Safety Monitoring Board (DSMB) reported that while there were no safety concerns, the trial is not likely to meet its primary endpoint.

The trial has not yet accrued data on the secondary endpoints, and the company will still carry out the study using the 223 patients that are already enrolled.